At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Predicting Aromatase Inhibitor Responsiveness in Endometrial Carcinoma
In Brief
A clinical study evaluating Letrozole for Endometrial Carcinoma. Completed, enrolled 43 participants across 2 sites.
Detailed Summary
Some cases of endometrial cancer are dependent on estrogen for their growth. Letrozole blocks estrogen production in the body. The purpose of this study is to determine if the investigators can predict which patients might benefit from Letrozole treatment by studying the many different forms of the estrogen receptor molecule that exist within the cancer tissues. To participate in this study, the patients must be 40 years of age or older and have biopsy-proven endometrial carcinoma, either well differentiated or moderately differentiated forms. Also, to be eligible to participate in this study, the patients need to be healthy enough to have a hysterectomy. If the patients are less than age 60, they will need a blood test (FSH) to confirm that they have gone into menopause.
Study Details
Timeline
Interventions
2.5 mg daily from the day of enrollment to the day before surgery, generally about 3 weeks